Cipla USA Initiates Class II Recall for Ipratropium Bromide and Albuterol Sulfate Inhalation Solution Due to Short-Fill
Cipla USA, Inc. has initiated a Class II recall (D-0471-2024) for Ipratropium Bromide and Albuterol Sulfate Inhalation Solution USP due to short-fill complaints. This voluntary, firm-initiated action, impacting 59,244 packs nationwide, highlights critical quality control vulnerabilities for respiratory therapeutics. Procurement and regulatory teams must scrutinize supplier quality systems to mitigate supply chain risks.
Cipla USA Initiates Class II Recall for Ipratropium Bromide and Albuterol Sulfate Inhalation Solution
Cipla USA, Inc. has initiated a voluntary, firm-initiated Class II recall, designated D-0471-2024, for its Ipratropium Bromide and Albuterol Sulfate Inhalation Solution USP, 0.5 mg & 3mg/3mL unit-dose vials. This critical regulatory action, initiated on March 26, 2024, and subsequently terminated on July 9, 2025, impacts a significant volume of product distributed nationwide across the USA. The recall specifically targets 59,244 /3ml FFS packs, encompassing Lot # IA30390 (Exp 4/30/2025) and Lot # IA30517 (Exp 6/30/2025). The product, identified by NDC 69097-173-53 and application number ANDA077559, is a human prescription drug administered via the respiratory (inhalation) route, manufactured by Cipla Ltd. in Indore SEZ, Pithampur, India, for Cipla USA, Inc. For procurement directors and supply chain VPs, this event underscores the imperative for continuous vigilance over outsourced manufacturing, particularly for high-volume generic respiratory therapeutics where consistent dosing is paramount for patient efficacy and safety. The Class II classification indicates that the product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote, yet the disruption to supply and patient trust remains a tangible business risk.
Quality Control Lapses: Short-Fill Defects in Inhalation Solutions
The primary reason for Cipla USA’s recall of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution is documented as a “short fill” issue. This defect manifests as complaints of less fill volume within the respule and, in some instances, the observation of a few drops of liquid in the intact pouch. For regulatory affairs heads and business development executives, this points directly to potential failures in the manufacturing process's fill-volume control and packaging integrity at the Cipla Ltd. facility in India. Inconsistent fill volumes for inhalation solutions can lead to sub-potent dosing for patients, potentially compromising therapeutic efficacy for conditions managed by these critical respiratory drugs. Conversely, leakage, even minor, indicates a breach in sterile packaging, raising concerns about product sterility and stability over its shelf life. Such quality control lapses necessitate a thorough review of automated filling lines, in-process controls, and final product inspection protocols. Companies sourcing similar products must reassess their supplier audit programs to specifically target and verify the robustness of these critical manufacturing parameters, ensuring that quality agreements explicitly address acceptable fill tolerances and packaging integrity standards to prevent similar disruptions.
Supply Chain Implications for Respiratory Drug Procurement
The nationwide distribution of the recalled Ipratropium Bromide and Albuterol Sulfate Inhalation Solution by Cipla USA, Inc. signifies a broad impact on the US market for respiratory generics. Procurement directors must recognize that a recall of this magnitude, involving a widely used combination bronchodilator, can strain existing supply chains and potentially lead to temporary shortages or increased demand on alternative suppliers. While the recall is now terminated, the initial disruption required immediate action to quarantine affected lots and manage inventory. This event highlights the inherent risks associated with single-source or concentrated manufacturing hubs, particularly those located internationally. Supply chain VPs should leverage this incident to re-evaluate their risk mitigation strategies, focusing on diversifying sourcing for essential generic drugs like Ipratropium Bromide and Albuterol Sulfate. Implementing rigorous quality assurance processes, including enhanced pre-shipment inspections and robust supplier performance monitoring, becomes paramount. The financial implications extend beyond direct recall costs, encompassing potential reputational damage, increased regulatory scrutiny, and the operational burden of managing product returns and replacements across the distribution network.
Post-Recall Status and Ongoing Due Diligence for Buyers
The FDA’s classification of this recall as “Terminated” as of July 9, 2025, indicates that Cipla USA, Inc. has completed the recall activities to the satisfaction of the agency, meaning all reasonable efforts have been made to remove or correct the product. However, for procurement directors and regulatory affairs heads, the termination status does not absolve the need for ongoing due diligence. The period from recall initiation (March 26, 2024) to termination (July 9, 2025) allowed for the identification, notification, and removal of affected product from distribution channels. Companies that procured these specific lots (IA30390 and IA30517) must ensure their internal systems accurately reflect the recall’s resolution and verify that no affected product remains in their inventory or has reached end-users. Furthermore, this event should prompt a review of Cipla USA’s corrective and preventive actions (CAPA) to address the root cause of the short-fill issue. Future procurement decisions should be informed by a comprehensive understanding of these remediation efforts, ensuring the manufacturer has implemented sustainable improvements to prevent recurrence and maintain consistent product quality for Ipratropium Bromide and Albuterol Sulfate and other critical therapeutics.
Broader Regulatory Environment for Pharmaceutical Manufacturing
This Class II recall by Cipla USA, Inc. occurs within a broader landscape of heightened regulatory scrutiny on pharmaceutical manufacturing quality, particularly for generic drugs. While this specific recall addresses a physical defect, it aligns with a persistent trend of regulatory actions across the industry. Recent parallel events, such as Essential Wellness Pharma's Class II recall for Progesterone Injection due to sterility assurance failures and the FDA's hearing on Amgen's Tavneos market future, underscore the agency's unyielding focus on product quality, safety, and manufacturing compliance. For business development executives and supply chain VPs, these events collectively signal that regulatory bodies like the FDA are intensifying oversight, demanding robust quality management systems from manufacturers globally. Companies must anticipate and prepare for increased audit frequencies, more stringent data integrity requirements, and a lower tolerance for deviations. Proactive investment in quality infrastructure, comprehensive risk assessments of manufacturing partners, and transparent communication with regulatory bodies are no longer optional but essential strategies to safeguard market access and ensure uninterrupted supply of critical pharmaceutical products.